A trial of emibetuzumab for non small cell lung cancer that had stopped responding to erlotinib (CHIME)

Overview

Cancer types:

Lung cancer, Non small cell lung cancer (NSCLC)

Status:

Results

Phase:

Phase 2

Details

This trial looked at emibetuzumab for non small cell lung cancer which had spread and got worse despite having erlotinib. It was for people who had change to a called MET in their lung cancer cells.

It was open for people to join between 2013 and 2014. The team presented the results at a conference in 2016. There is a link to more information in the ‘Summary of results’ section below.

Recruitment start: 1 December 2013

Recruitment end: 29 August 2014